Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety/tolerability/feasibility of pembrolizumab
and radiation therapy before surgical resection in patients with recurrent glioblastoma as
defined by treatment-related AEs and the number of patients who do not necessitate a delay in
surgical resection, and to assess overall survival. The secondary objectives are to assess
progression free survival, and to assess the T cell clonality, CD8 T cell activation and
Tumor Infiltrating Lymphocyte (TIL) score after treatment